Post Profile






Medical News Today: Head and neck cancer: Immunotherapy drug a 'game-changer' for survival

A phase III trial of patients with head and neck cancer reveals the immunotherapy drug nivolumab greatly extended survival, compared with chemotherapy.
read more

share

Related Posts


Immunotherapy drug a 'gamechanger' for head and neck cancer

Health : The Guardian: Health

Nivolumab found to extend lives of relapsed patients who had run out of therapy options An immunotherapy drug hailed as a potential “gamechanger” in the treatment of cancer could soon offer new hope to patients with currently untrea...

Immunotherapy Drug Improves Survival for Common Form of Lung Cancer

Health : Newswise Medical News

In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months long...

'Game-changing' immunotherapy doubles head and neck cancer survival

Health : EurekAlert: Health

(Institute of Cancer Research) An immunotherapy drug has been hailed as a potential 'game changer' after being found to greatly improve survival for patients with relapsed head and neck cancer -- a disease which is notoriously diffi...

Medical News Today: Study finds drug improves survival for patients with non-small cell lung cancer

Health : Medical News Today

A new phase 3 trial finds that overall survival is longer for patient with non-small cell lung cancer treated with the drug nivolumab compared with chemotherapy drug docetaxel.

Immunotherapy is first to show survival benefit in head and neck cancer

Academics / General Science : Science Codex

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. Patients taking nivolumab were ...

Comments


Copyright © 2016 Regator, LLC